Chemotherapy in patients older than or equal to 75 years with advanced non-small cell lung cancer

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose As the number of elderly patients diagnosed with non-small cell lung carcinoma (NSCLC) increases, the number of these patients receiving chemotherapy also increases. However, limited data exists regarding the use of chemotherapy in advanced NSCLC patients who are 75 years of age or older. Materials and Methods Between May 2002 and October 2008, data for 48 advanced NSCLC patients who were 75 years of age or older who had been treated with chemotherapy were retrospectively analyzed. Results The median age of study participants at the time of first line chemotherapy was 76 years (range, 75 to 87 years) and their median Charlson comorbidity index was 2 (range, 1 to 4). Of the total 48 patients, 43 patients (90%) were treated by platinum-based doublet as a first line chemotherapy regimen. Median progression free survival for first line chemotherapy was 5.7 months (95% confidence interval [CI], 4.93 to 6.47 months) with an overall response rate of 33.3%. After first line chemotherapy, only 14 of the 48 patients (29.2%) received second line chemotherapy. The median overall survival (OS) for these patients was 8.2 months (95% CI, 4.44 to 11.96 months). Multivariate analysis results indicated that female gender and having received second-line or more chemotherapy were independent prognostic factors for increased OS for all 48 patients. Charlson Index was not a significant independent prognostic factor for survival. There were 9 treatment related deaths due to infectious causes (18.8%). Conclusion Patients 75 years of age or older with advanced NSCLC may obtain clinical benefit from the administration of platinum-based doublet or single agent chemotherapy. However, oncologists must consider the aspect of safety in relation to the clinical benefits when managing this patient group.

Original languageEnglish
Pages (from-to)37-42
Number of pages6
JournalCancer Research and Treatment
Volume44
Issue number1
DOIs
Publication statusPublished - 2012 Mar 1

Fingerprint

Non-Small Cell Lung Carcinoma
Drug Therapy
Platinum
Survival
Confidence Intervals
Disease-Free Survival
Comorbidity
Multivariate Analysis
Safety

Keywords

  • Aged
  • Drug therapy
  • Non-small-cell lung carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{33f07e1d8e074547b212fdb39f2a26a4,
title = "Chemotherapy in patients older than or equal to 75 years with advanced non-small cell lung cancer",
abstract = "Purpose As the number of elderly patients diagnosed with non-small cell lung carcinoma (NSCLC) increases, the number of these patients receiving chemotherapy also increases. However, limited data exists regarding the use of chemotherapy in advanced NSCLC patients who are 75 years of age or older. Materials and Methods Between May 2002 and October 2008, data for 48 advanced NSCLC patients who were 75 years of age or older who had been treated with chemotherapy were retrospectively analyzed. Results The median age of study participants at the time of first line chemotherapy was 76 years (range, 75 to 87 years) and their median Charlson comorbidity index was 2 (range, 1 to 4). Of the total 48 patients, 43 patients (90{\%}) were treated by platinum-based doublet as a first line chemotherapy regimen. Median progression free survival for first line chemotherapy was 5.7 months (95{\%} confidence interval [CI], 4.93 to 6.47 months) with an overall response rate of 33.3{\%}. After first line chemotherapy, only 14 of the 48 patients (29.2{\%}) received second line chemotherapy. The median overall survival (OS) for these patients was 8.2 months (95{\%} CI, 4.44 to 11.96 months). Multivariate analysis results indicated that female gender and having received second-line or more chemotherapy were independent prognostic factors for increased OS for all 48 patients. Charlson Index was not a significant independent prognostic factor for survival. There were 9 treatment related deaths due to infectious causes (18.8{\%}). Conclusion Patients 75 years of age or older with advanced NSCLC may obtain clinical benefit from the administration of platinum-based doublet or single agent chemotherapy. However, oncologists must consider the aspect of safety in relation to the clinical benefits when managing this patient group.",
keywords = "Aged, Drug therapy, Non-small-cell lung carcinoma",
author = "Kim, {Seung Tae} and Park, {Kyong Hwa} and Oh, {Sang Cheul} and Seo, {Jae Hong} and Kim, {Jun Suk} and Kim, {Yeul Hong} and Shin, {Sang Won}",
year = "2012",
month = "3",
day = "1",
doi = "10.4143/crt.2012.44.1.37",
language = "English",
volume = "44",
pages = "37--42",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Society for Thoracic and Cardiovascular Surgery",
number = "1",

}

TY - JOUR

T1 - Chemotherapy in patients older than or equal to 75 years with advanced non-small cell lung cancer

AU - Kim, Seung Tae

AU - Park, Kyong Hwa

AU - Oh, Sang Cheul

AU - Seo, Jae Hong

AU - Kim, Jun Suk

AU - Kim, Yeul Hong

AU - Shin, Sang Won

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Purpose As the number of elderly patients diagnosed with non-small cell lung carcinoma (NSCLC) increases, the number of these patients receiving chemotherapy also increases. However, limited data exists regarding the use of chemotherapy in advanced NSCLC patients who are 75 years of age or older. Materials and Methods Between May 2002 and October 2008, data for 48 advanced NSCLC patients who were 75 years of age or older who had been treated with chemotherapy were retrospectively analyzed. Results The median age of study participants at the time of first line chemotherapy was 76 years (range, 75 to 87 years) and their median Charlson comorbidity index was 2 (range, 1 to 4). Of the total 48 patients, 43 patients (90%) were treated by platinum-based doublet as a first line chemotherapy regimen. Median progression free survival for first line chemotherapy was 5.7 months (95% confidence interval [CI], 4.93 to 6.47 months) with an overall response rate of 33.3%. After first line chemotherapy, only 14 of the 48 patients (29.2%) received second line chemotherapy. The median overall survival (OS) for these patients was 8.2 months (95% CI, 4.44 to 11.96 months). Multivariate analysis results indicated that female gender and having received second-line or more chemotherapy were independent prognostic factors for increased OS for all 48 patients. Charlson Index was not a significant independent prognostic factor for survival. There were 9 treatment related deaths due to infectious causes (18.8%). Conclusion Patients 75 years of age or older with advanced NSCLC may obtain clinical benefit from the administration of platinum-based doublet or single agent chemotherapy. However, oncologists must consider the aspect of safety in relation to the clinical benefits when managing this patient group.

AB - Purpose As the number of elderly patients diagnosed with non-small cell lung carcinoma (NSCLC) increases, the number of these patients receiving chemotherapy also increases. However, limited data exists regarding the use of chemotherapy in advanced NSCLC patients who are 75 years of age or older. Materials and Methods Between May 2002 and October 2008, data for 48 advanced NSCLC patients who were 75 years of age or older who had been treated with chemotherapy were retrospectively analyzed. Results The median age of study participants at the time of first line chemotherapy was 76 years (range, 75 to 87 years) and their median Charlson comorbidity index was 2 (range, 1 to 4). Of the total 48 patients, 43 patients (90%) were treated by platinum-based doublet as a first line chemotherapy regimen. Median progression free survival for first line chemotherapy was 5.7 months (95% confidence interval [CI], 4.93 to 6.47 months) with an overall response rate of 33.3%. After first line chemotherapy, only 14 of the 48 patients (29.2%) received second line chemotherapy. The median overall survival (OS) for these patients was 8.2 months (95% CI, 4.44 to 11.96 months). Multivariate analysis results indicated that female gender and having received second-line or more chemotherapy were independent prognostic factors for increased OS for all 48 patients. Charlson Index was not a significant independent prognostic factor for survival. There were 9 treatment related deaths due to infectious causes (18.8%). Conclusion Patients 75 years of age or older with advanced NSCLC may obtain clinical benefit from the administration of platinum-based doublet or single agent chemotherapy. However, oncologists must consider the aspect of safety in relation to the clinical benefits when managing this patient group.

KW - Aged

KW - Drug therapy

KW - Non-small-cell lung carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84866893328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866893328&partnerID=8YFLogxK

U2 - 10.4143/crt.2012.44.1.37

DO - 10.4143/crt.2012.44.1.37

M3 - Article

C2 - 22500159

AN - SCOPUS:84866893328

VL - 44

SP - 37

EP - 42

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 1

ER -